Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6329579
Reference Type
Journal Article
Title
Enhancement of the intestinal absorption of peptides and nonpeptides
Author(s)
Aungst, BJ; Saitoh, H; Burcham, DL; Huang, SM; Mousa, SA; Hussain, MA
Year
1996
Is Peer Reviewed?
Yes
Journal
Journal of Controlled Release
ISSN:
0168-3659
EISSN:
1873-4995
Publisher
ELSEVIER SCIENCE BV
Location
AMSTERDAM
Volume
41
Issue
1-2
Page Numbers
19-31
DOI
10.1016/0168-3659(96)01353-3
Web of Science Id
WOS:A1996VB46400003
Abstract
It is not uncommon for peptides and structurally-similar non-peptides to have poor intestinal permeability and low oral bioavailability. One possible way to solve a permeability problem is to formulate the compound with membrane permeation-enhancing excipients. Important criteria for success of this approach are: (1) achieving reproducible intestinal permeation, (2) doing so without causing toxicity, and (3) understanding the mechanisms of permeation enhancement. Some effective and potentially safe permeation enhancers are fatty acids, glycerides, surfactants, acyl carnitines, and bile salts. The literature on permeation enhancement with these agents is briefly reviewed. We evaluated permeation enhancement approaches to increase the oral bioavailability of a non-metabolized, cyclic peptide fibrinogen antagonist, DMP 728. Sodium caprate (15 mM) increased the in vitro intestinal permeation rate 3-fold. Oral absorption in dogs was also increased approximately 3-fold using a formulation containing 150 mg sodium caprate. Inter-animal variability in absorption was considerable, though. A diacidic, non-peptide angiotensin II antagonist, DuP 532, presented another case of a poorly membrane permeable lead compound. Sodium caprate did not affect DuP 532 oral bioavailability in rats. However, oral bioavailability of DuP 532 in rats and dogs was increased approximately 3-fold using glyceride vehicles. These excipients have the advantage of already being used in marketed products. As with DMP 728, there was substantial inter-animal variability of DuP 532 oral bioavailability, and optimization of the formulation would be required to improve reproducibility. These examples demonstrate the possibilities of significantly improving oral bioavailability of poorly permeable drugs using seemingly acceptable excipients.
Keywords
oral absorption; intestinal permeation; enhancement; bioavailability
Conference Name
5th International Symposium on Delivery and Targeting of Peptides, Proteins and Genes
Conference Location
LEIDEN, NETHERLANDS
Tags
PFAS
•
Additional PFAS (formerly XAgency)
•
PFAS Universe
Data Source
Web of Science
2-Propyl-4-pentafluoroethyl-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity